Portrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents downstream activity in parts of the EGFR pathway that are responsible for cellular proliferation, differentiation, and metastasis. The drug also has the potential to produce antibody-dependent cell-mediated cytotoxicity in cancer cells that express EGFR. Portrazza is a follow-up product to Erbitux (cetuximab; Eli Lilly/Merck KGaA), but unlike its predecessor it is a fully human MAb. Ideally, this allows Portrazza to have higher anti-tumor effects while presenting a lower risk for hypersensitivity.
4 Drug Overview
5 Product Profiles
5 Portrazza : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 87: Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
11 Figure 89: Cemiplimab for non-small cell lung cancer – SWOT analysis
13 Figure 90: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
LIST OF TABLES
5 Table 1: Portrazza drug profile
7 Table 2: Portrazza pivotal trial data in non-small cell lung cancer
14 Table 3: Portrazza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 4: Portrazza patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.